

From: Carolyn Balkenhol <cbalkenhol@theranos.com>
Sent: Thursday, April 1, 2010 2:51 PM
To: Victoria Sung <VSung@celgene.com>
Subject: RE: Celgene Clinical Trial - PD marker development

Excellent, thanks! We are really looking forward to it.

Carolyn

From: Victoria Sung [mailto:VSung@celgene.com]
Sent: Thursday, April 01, 2010 2:46 PM
To: Carolyn Balkenhol
Subject: RE: Celgene Clinical Trial - PD marker development

Hi Carolyn,
Thank you for getting back to me and for confirming April 27. Why don't we plan for 1-4 in the afternoon? We can always end early if we find we don't need the full amount of time. From Celgene, it will be me, Sharienne Louie (a manager from the Translational Development Operations group) and Lea Aukerman (senior director, Translational Development). It is possible that we may have a consultant dialing in as well but I'll have to double check on that.
Best regards,
Vicki

From: Carolyn Balkenhol [mailto:cbalkenhol@theranos.com]
Sent: Wednesday, March 31, 2010 7:53 PM
To: Victoria Sung
Subject: RE: Celgene Clinical Trial - PD marker development

Vicki,

Thank you SO MUCH for your patience! I finally have all the schedules in order and am happy to confirm the meeting for the afternoon of Tuesday, April 27th – here at Theranos in Palo Alto. Please let me know what specific timing will work best for you and the team – and who will be joining you.

We are looking forward to having you here.

Thanks again,
Carolyn

From: Carolyn Balkenhol
Sent: Wednesday, March 24, 2010 2:37 PM
To: 'Victoria Sung'
Subject: RE: Celgene Clinical Trial - PD marker development

I did get it – I'm sorry I'm taking so long. There are so many scheduling issues that I'm trying to be sure I get them all settled before we lock it in. Thanks for your patience.

Carolyn

From: Victoria Sung [mailto:VSung@celgene.com]
Sent: Wednesday, March 24, 2010 2:23 PM
To: Carolyn Balkenhol
Subject: RE: Celgene Clinical Trial - PD marker development

Hi Caroline,
Just checking to make sure that you received my e-mail from last Friday, in which I confirmed that the afternoon of April 27 should work for a face-to-face meeting? I sent the message late in the day using my blackberry, which has recently been inconsistent...
Thanks,
Vicki

From: Carolyn Balkenhol [mailto:cbalkenhol@theranos.com]
Sent: Thursday, March 18, 2010 9:45 AM
To: Victoria Sung
Subject: RE: Celgene Clinical Trial - PD marker development

Excellent, thanks.

From: Victoria Sung [mailto:VSung@celgene.com]
Sent: Thursday, March 18, 2010 9:42 AM
To: Carolyn Balkenhol
Subject: RE: Celgene Clinical Trial - PD marker development

Hi Carolyn,
I'm just double checking with my colleagues on the two dates; I hope to get back to you by tomorrow, at the latest.

Thank YOU for being patient with us.
Vicki

From: Carolyn Balkenhol [mailto:cbalkenhol@theranos.com]
Sent: Wednesday, March 17, 2010 12:40 PM
To: Victoria Sung
Subject: RE: Celgene Clinical Trial - PD marker development

Would the afternoon of the 27th work? If not, how about the morning of the 29th?

Thanks for your patience as we narrow in on the right date!
Carolyn

From: Victoria Sung [mailto:VSung@celgene.com]
Sent: Tuesday, March 16, 2010 3:39 PM
To: Carolyn Balkenhol
Subject: RE: Celgene Clinical Trial - PD marker development

Hi Carolyn,
Thank you for getting back to me. AACR is held through the 21st so a couple of us will not be back until later that week. The 23rd works for two of us but not the third...how about the morning of the 27th? I'm assuming that there is not availability earlier in April?
Best,
Vicki

From: Carolyn Balkenhol [mailto:cbalkenhol@theranos.com]
Sent: Tuesday, March 16, 2010 3:25 PM
To: Victoria Sung
Subject: FW: Celgene Clinical Trial - PD marker development

Vicki,
How about 4/21 or 4/23 (I'm not sure whether it can be ON the 21st or needs to be after...)?

Thanks,
Carolyn

From: Elizabeth Holmes
Sent: Wednesday, March 10, 2010 9:28 AM
To: Carolyn Balkenhol
Subject: FW: Celgene Clinical Trial - PD marker development

From: Victoria Sung [mailto:VSung@celgene.com]

Sent: Wednesday, March 10, 2010 9:26 AM
To: Gary Frenzel; Surekha Gangakhedkar; Elizabeth Holmes
Subject: Celgene Clinical Trial - PD marker development

Hi Gary, Surekha and Elizabeth,
Hope you are all doing well. We have finally awarded a contract to ACM, who will be our central lab for the renal study, and are ready to touch base with you regarding setting up an assay validation plan, timelines, etc.. I think another face-to-face meeting will be the best way to kick off this process so would you please send me a few dates that will work for the three of you and anyone else who might be relevant to this process? We are looking at the weeks of March 29, April 5 (second half of the week), April 12 and April 19 (after the 21st). I'm hoping that Lea, Sharienne and I (at the least) will be able to meet with you; the new ACE-011 PTL is also planning a trip to SF some time soon, so he may also be interested in joining.

I'm glad that we're finally able to move forward; sorry it has taken us so long to get our act together! I'm looking forward to catching up with you again and to hear how the PD marker development is progressing.

Best regards,
Vicki

THIS ELECTRONIC MAIL MESSAGE AND ANY ATTACHMENT IS
CONFIDENTIAL AND MAY CONTAIN LEGALLY PRIVILEGED
INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL
OR INDIVIDUALS NAMED ABOVE.
If the reader is not the intended recipient, or the
employee or agent responsible to deliver it to the
intended recipient, you are hereby notified that any
dissemination, distribution or copying of this
communication is strictly prohibited. If you have
received this communication in error, please reply to the
sender to notify us of the error and delete the original
message. Thank You.

THIS ELECTRONIC MAIL MESSAGE AND ANY ATTACHMENT IS
CONFIDENTIAL AND MAY CONTAIN LEGALLY PRIVILEGED
INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL
OR INDIVIDUALS NAMED ABOVE.
If the reader is not the intended recipient, or the
employee or agent responsible to deliver it to the
intended recipient, you are hereby notified that any
dissemination, distribution or copying of this
communication is strictly prohibited. If you have
received this communication in error, please reply to the
sender to notify us of the error and delete the original
message. Thank You.

THIS ELECTRONIC MAIL MESSAGE AND ANY ATTACHMENT IS
CONFIDENTIAL AND MAY CONTAIN LEGALLY PRIVILEGED
INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL
OR INDIVIDUALS NAMED ABOVE.
If the reader is not the intended recipient, or the
employee or agent responsible to deliver it to the
intended recipient, you are hereby notified that any
dissemination, distribution or copying of this
communication is strictly prohibited. If you have
received this communication in error, please reply to the
sender to notify us of the error and delete the original
message. Thank You.

THIS ELECTRONIC MAIL MESSAGE AND ANY ATTACHMENT IS
CONFIDENTIAL AND MAY CONTAIN LEGALLY PRIVILEGED
INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL
OR INDIVIDUALS NAMED ABOVE.
If the reader is not the intended recipient, or the
employee or agent responsible to deliver it to the

intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender to notify us of the error and delete the original message. Thank You.

THIS ELECTRONIC MAIL MESSAGE AND ANY ATTACHMENT IS CONFIDENTIAL AND MAY CONTAIN LEGALLY PRIVILEGED INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR INDIVIDUALS NAMED ABOVE.

If the reader is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender to notify us of the error and delete the original message. Thank You.
